Kieran F Geoghegan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11687710/publications.pdf

Version: 2024-02-01

172457 133252 5,037 60 29 59 citations h-index g-index papers 62 62 62 6299 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Identification, Characterization, and Crystal Structure of the Omega Class Glutathione Transferases. Journal of Biological Chemistry, 2000, 275, 24798-24806.	3.4	625
2	Structural basis of latency in plasminogen activator inhibitor-1. Nature, 1992, 355, 270-273.	27.8	565
3	X-ray analysis of HIV-1 proteinase at 2.7 \tilde{A} resolution confirms structural homology among retroviral enzymes. Nature, 1989, 342, 299-302.	27.8	477
4	Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nature Structural and Molecular Biology, 2007, 14, 413-419.	8.2	378
5	Site-directed conjugation of nonpeptide groups to peptides and proteins via periodate oxidation of a 2-amino alcohol. Application to modification at N-terminal serine. Bioconjugate Chemistry, 1992, 3, 138-146.	3.6	339
6	Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nature Structural and Molecular Biology, 2007, 14, 106-113.	8.2	238
7	Kinetic analysis of estrogen receptor/ligand interactions. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 8562-8567.	7.1	210
8	Spontaneous α-N-6-Phosphogluconoylation of a "His Tag―inEscherichia coli:The Cause of Extra Mass of 258 or 178 Da in Fusion Proteins. Analytical Biochemistry, 1999, 267, 169-184.	2.4	190
9	Glutathione S-Transferase Omega 1-1 Is a Target of Cytokine Release Inhibitory Drugs and May Be Responsible for Their Effect on Interleukin-1ठPosttranslational Processing. Journal of Biological Chemistry, 2003, 278, 16567-16578.	3.4	180
10	Structural Basis for AMPK Activation: Natural and Synthetic Ligands Regulate Kinase Activity from Opposite Poles by Different Molecular Mechanisms. Structure, 2014, 22, 1161-1172.	3. 3	159
11	Rational Targeting of Active-Site Tyrosine Residues Using Sulfonyl Fluoride Probes. ACS Chemical Biology, 2015, 10, 1094-1098.	3.4	153
12	Concentration-Dependent Modulation of Amyloid- \hat{l}^2 in Vivo and in Vitro Using the \hat{l}^3 -Secretase Inhibitor, LY-450139. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 924-933.	2.5	127
13	Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition. ACS Chemical Biology, 2016, 11, 3442-3451.	3.4	127
14	Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain. PLoS Biology, 2017, 15, e2001882.	5.6	104
15	Activation of Liver AMPK with PF-06409577 Corrects NAFLD and Lowers Cholesterol in Rodent and Primate Preclinical Models. EBioMedicine, 2018, 31, 122-132.	6.1	99
16	Distinctive Attributes of \hat{l}^2 -Lactam Target Proteins in <i>Acinetobacter baumannii</i> Relevant to Development of New Antibiotics. Journal of the American Chemical Society, 2011, 133, 20536-20545.	13.7	85
17	Synthesis and biological activity of selective pipecolic acid-based TNF-α converting enzyme (TACE) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 1387-1390.	2.2	76
18	Biochemical applications of mass spectrometry in pharmaceutical drug discovery. Mass Spectrometry Reviews, 2005, 24, 347-366.	5.4	74

#	Article	IF	Citations
19	Engineered stabilization and structural analysis of the autoinhibited conformation of PDE4. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1414-22.	7.1	68
20	The 2.0 \tilde{A} crystal structure of the ERα ligand-binding domain complexed with lasofoxifene. Protein Science, 2007, 16, 897-905.	7.6	54
21	Pharmacodynamics and Pharmacokinetics of the \hat{I}^3 -Secretase Inhibitor PF-3084014. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 269-277.	2.5	52
22	Reversible reductive alkylation of amino groups in proteins. Biochemistry, 1979, 18, 5392-5399.	2.5	48
23	Chemoproteomic Analysis of Intertissue and Interspecies Isoform Diversity of AMP-activated Protein Kinase (AMPK). Journal of Biological Chemistry, 2013, 288, 35904-35912.	3.4	46
24	Chemical Modification of Proteins: An Overview. Advances in Chemistry Series, 1982, , 3-55.	0.6	41
25	Site-directed double fluorescent tagging of human renin and collagenase (MMP-1) substrate peptides using the periodate oxidation of N-terminal serine. An apparently general strategy for provision of energy-transfer substrates for proteases. Bioconjugate Chemistry, 1993, 4, 537-544.	3.6	37
26	Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists. Scientific Reports, 2016, 6, 30859.	3.3	36
27	Expression of human plasminogen activator inhibitor type-1 (PAI-1) in Escherichia coli as a soluble protein comprised of active and latent forms. Isolation and crystallization of latent PAI-1. BBA - Proteins and Proteomics, 1990, 1037, 16-23.	2.1	33
28	ALTERNATIVE REDUCING AGENTS FOR REDUCTIVE METHYLATION OF AMINO GROUPS IN PROTEINS. International Journal of Peptide and Protein Research, 1981, 17, 345-352.	0.1	32
29	Dye-Pair Reporter Systems for Proteinâ^'Peptide Molecular Interactions. Bioconjugate Chemistry, 2000, 11, 71-77.	3.6	29
30	Fluorescence-based continuous assay for the aspartyl protease of human immunodeficiency virus-1. FEBS Letters, 1990, 262, 119-122.	2.8	22
31	Phosphorylation of serine residues in histidine-tag sequences attached to recombinant protein kinases: A cause of heterogeneity in mass and complications in function. Protein Expression and Purification, 2005, 44, 121-129.	1.3	22
32	Dominance of Amyloid Precursor Protein Sequence over Host Cell Secretases in Determining Î ² -Amyloid Profiles Studies of Interspecies Variation and Drug Action by Internally Standardized Immunoprecipitation/Mass Spectrometry. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 1144-1152.	2.5	22
33	Chemoproteomics Demonstrates Target Engagement and Exquisite Selectivity of the Clinical Phosphodiesterase 10A Inhibitor MP-10 in Its Native Environment. ACS Chemical Biology, 2014, 9, 2823-2832.	3.4	22
34	Crystallizable HIV-1 protease derived from expression of the viral pol gene in Escherichia coli. Biochemical and Biophysical Research Communications, 1989, 165, 1043-1050.	2.1	21
35	Escherichia coli expression, purification and characterization of functional full-length recombinant $\hat{1}\pm2\hat{1}^22\hat{1}^33$ heterotrimeric complex of human AMP-activated protein kinase. Protein Expression and Purification, 2010, 73, 189-197.	1.3	21
36	Deconstruction of Activity-Dependent Covalent Modification of Heme in Human Neutrophil Myeloperoxidase by Multistage Mass Spectrometry (MS ⁴). Biochemistry, 2012, 51, 2065-2077.	2.5	20

#	Article	IF	CITATIONS
37	Emerging Methods in Chemoproteomics with Relevance to Drug Discovery. Methods in Molecular Biology, 2017, 1513, 11-22.	0.9	20
38	Improved Method for Converting an Unmodified Peptide to an Energy-Transfer Substrate for a Proteinase. Bioconjugate Chemistry, 1996, 7, 385-391.	3.6	19
39	A Thermally Sensitive Loop in Clostridial Glutamate Dehydrogenase Detected by Limited Proteolysis. Journal of Biological Chemistry, 2003, 278, 1067-1074.	3.4	13
40	Biophysical and Biochemical Approach to Locating an Inhibitor Binding Site on Cholesteryl Ester Transfer Protein. Bioconjugate Chemistry, 2008, 19, 1604-1613.	3.6	13
41	Chemical and Biochemical Issues Related to X-ray Crystallography of the Ligand-Binding Domain of Estrogen Receptor α. Bioconjugate Chemistry, 2001, 12, 406-413.	3.6	12
42	MAP4K4 Is a Threonine Kinase That Phosphorylates FARP1. ACS Chemical Biology, 2015, 10, 2667-2671.	3.4	12
43	Unexpected mucin-type O-glycosylation and host-specific N-glycosylation of human recombinant interleukin-17A expressed in a human kidney cell line. Protein Expression and Purification, 2013, 87, 27-34.	1.3	11
44	A tag-free collisionally induced fragmentation approach to detect drug-adducted proteins by mass spectrometry. Rapid Communications in Mass Spectrometry, 2015, 29, 2175-2183.	1.5	11
45	A library approach to rapidly discover photoaffinity probes of the mRNA decapping scavenger enzyme DcpS. Molecular BioSystems, 2015, 11, 2709-2712.	2.9	11
46	Design and chemoproteomic functional characterization of a chemical probe targeted to bromodomains of BET family proteins. MedChemComm, 2014, 5, 1871-1878.	3.4	10
47	Chemical Proteomic Technologies for Drug Target Identification. Annual Reports in Medicinal Chemistry, 2010, , 345-360.	0.9	9
48	Direct photocapture of bromodomains using tropolone chemical probes. MedChemComm, 2015, 6, 1018-1023.	3.4	9
49	Modification of amyloid-β(1–40) by a protease inhibitor creates risk of error in mass spectrometric quantitation of amyloid-β(1–42). Analytical Biochemistry, 2008, 382, 147-149.	2.4	7
50	Investigating \hat{I}^3 -secretase protein interactions in live cells using active site-directed clickable dual-photoaffinity probes. MedChemComm, 2014, 5, 321-327.	3.4	7
51	Preliminary x-ray analysis of crystals of plasminogen activator inhibitor-1. Proteins: Structure, Function and Bioinformatics, 1991, 9, 225-227.	2.6	6
52	Tandem mass spectrometry of multiply phosphorylated forms of a ?histidine-tag? derived from a recombinant protein kinase expressed in bacteria. Rapid Communications in Mass Spectrometry, 2005, 19, 547-551.	1.5	6
53	Modification of Amino Groups. Current Protocols in Protein Science, 1996, 4, Unit15.2.	2.8	5
54	Expression and protein chemistry yielding crystallization of the catalytic domain of ADAM17 complexed with a hydroxamate inhibitor. Protein Expression and Purification, 2007, 52, 313-319.	1.3	5

#	Article	IF	CITATIONS
55	Binding to the Low-Density Lipoprotein Receptor Accelerates Futile Catalytic Cycling in PCSK9 and Raises the Equilibrium Level of Intramolecular Acylenzyme. Biochemistry, 2009, 48, 2941-2949.	2.5	5
56	A continuous and direct assay to monitor leucine-rich repeat kinase 2 activity. Analytical Biochemistry, 2014, 450, 63-69.	2.4	5
57	Initiation of translation at an upstream non-AUG codon accounting for N-terminally extended minor forms of recombinant proteins expressed in insect cells. Protein Expression and Purification, 2011, 76, 72-78.	1.3	4
58	Modification of Amino Groups. Current Protocols in Protein Science, 2016, 86, 15.2.1-15.2.20.	2.8	4
59	32 Probing the stability of the tertiary structure of glutamate dehydrogenase by limited proteolysis. Biochemical Society Transactions, 1998, 26, S26-S26.	3.4	1
60	Selective Sequencing of Peptides with N-Terminal Ser or Thr in Mixtures. Techniques in Protein Chemistry, 1994, , 151-158.	0.3	0